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Neoplasms arising from melanocytes in the skin may 
be benign, in which case they are termed "nevi", or 
malignant, in which case they are termed "melanomas". 
There are several variants of cutaneous melanocytic 
tumors, characterized by differing clinical and 
pathologic features. Spitz tumors include a group of 
cutaneous melanocytic tumors that share certain 
histologic features. Spitz tumors may be classified as 
Spitz nevi [which are benign], spitzoid melanomas 
[which are malignant], and "atypical Spitz tumor" [a 
group of tumors whose biologic behavior cannot be 
accurately predicted on the basis of their 
histopathologic features] (Barnhill, 2006a; Barnhill, 
2006b). Spitz nevi show characteristic cytologic and 
architectural features, described below. Only some of 
these characteristics are seen in atypical Spitz tumors 
and spitzoid melanomas. 
Clinics and pathology 
Note 
The diagnosis of Spitz tumors may be suspected on 
clinical grounds, as these tumors can have distinctive 
clinical appearances. Characteristic clinical features 
include onset during childhood, small ( 
The histopathologic evaluation of melanocytic tumors 
of the skin relies on assessment of several architectural 
and cytologic features, some of which are characteristic 
of nevi, while others are of melanomas. Spitz tumors 
are a unique subtype of melanocytic tumors in that 
tumors at the benign end of the spectrum [Spitz nevi] 
still commonly exhibit morphologic features that are 
often seen in melanomas. These include cytologic 
characteristics such as large cell size, abundant 
cytoplasm, large, often vesicular, nuclei, intranuclear 
pseudoinclusions and sometimes prominent nucleoli; 
this constellation of cytologic features is often referred 
to as "spitzoid". Other features include lack of 
pigmentation (with the exception of the "pigmented 
spindle cell nevus", thought to be a Spitz nevus 
variant), peripheral circumscription (cell aggregates 
rather than single cells mark the periphery of the 
epidermal component), symmetry, clefts around cells 
and aggregates of cells (particularly at the dermo-
epidermal junction), so-called Kamino bodies 
(basement membrane-like material found in the 
superficial dermis), epidermal changes (thickening and 
hypergranulosis), "maturation" of any dermal 
component (the cells tend to get smaller with less 
cytoplasm in the deeper dermal portion) and single cell 
dispersion at the base of the lesion. Spitz nevi can also 
have an increased number of mitotic figures, consistent 
with their comparatively rapid, but ultimately self-
limited, growth.  
In 1948, Sophie Spitz originally described an unusual 
melanocytic tumor that occurred in children and was 
characterized by distinctive cytoarchitectural features, 
many of which were thought to be unique to melanoma. 
Spitz therefore termed these tumors "juvenile 
melanomas" (Spitz, 1948).  
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Figure 1. Spitz nevus on the right cheek of a young girl. The tumor is small, symmetrical, and dome-shaped, and lacks pigmentation. 
 
In subsequent years, with the realization that the 
majority of these tumors followed a benign course 
(Allen and Spitz, 1953), they were designated "Spitz 
nevi". 
Since that time, pathologists have identified spitzoid 
cytologic features in melanocytic tumors that lack the 
classical diagnostic criteria for Spitz nevi. Some of 
these tumors show sufficient cytologic atypia and 
mitotic activity to merit classification as melanoma 
["spitzoid melanoma"] and behave clinically in a 
malignant fashion (development of distant metastasis 
and patient death). These spitzoid melanomas include 
melanomas that arise from pre-existing Spitz nevi as 
well as melanomas with spitzoid morphologic features 
that arise de novo, without an antecedent Spitz nevus 
(Kamino, 2009). Other Spitz tumors show greater 
degrees of cytologic atypia and mitotic activity than 
permissible for nevi, but falling short of that required 
for a definite diagnosis of melanoma. Several studies 
have shown that in such tumors, correlation of 
histopathologic features with clinical outcomes is poor, 
and therefore they have been designated "atypical Spitz 
tumors of uncertain malignant potential" [or simply 
"atypical Spitz tumors"] to reflect the uncertainty 
regarding their likely clinical behavior. Part of the 
difficulty arises because there is not a single 
histological feature that in isolation defines either a 
Spitz nevus or a melanoma. Rather, a credible 
pathologic diagnosis of a melanocytic tumor requires 
assessment and consideration of a range of architectural 
and cytologic features as well as correlation with 
clinical data including the age of the patient and site of 
the lesion. 
Given the aforementioned considerations, it is perhaps 
not surprising that the histologic grading of Spitz 
tumors as benign [Spitz nevi], malignant [spitzoid 
melanoma] or tumors of intermediate/uncertain 
malignant potential [AST] is poorly reproducible 
between pathologists, even among experts in 
melanocytic tumor pathology (Barnhill et al., 1999; 
Cerroni et al., 2010). ASTs in particular constitute a 
heterogeneous group of tumors with imperfectly 
defined diagnostic criteria. Therefore, there is a need 
for better genetic and molecular characterization of 
Spitz tumors, along with genotype-phenotype 
correlations, in order to improve the precision of their 
classification and also to more accurately predict their 
biologic behavior. Recent discoveries of genetic 




Usually in fair-skinned individuals. May be seen at any 
age, but are commonest in children and young adults. 
Between half and two-thirds of cases occur in the first 
two decades (Lyon, 2010). 
Clinics 
Spitz nevi present as single, dome-shaped papule or 
nodule typically <6mm in diameter. Most often, they 
occur on the face but can occur at any cutaneous 
location. Commonly, they are not pigmented, but may 
have a pink to reddish color. Some lesions are heavily 
pigmented, but those typically fall under the category 
of pigmented spindle cell nevus (Ferrara et al., 2005; 
Mooi, 2002). Unusual clinical presentations include 
grouped/agminated Spitz nevi (Herd et al., 1994; 
Krasovec et al., 1995) or disseminated Spitz nevi (Rim 
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et al., 2002; Smith et al., 1986), which may develop 
abruptly [eruptive Spitz nevi] (Gantner et al., 2011; 
Levy et al., 2007). 
Pathology 
Spitz nevi usually involve both the epidermis and 
dermis (i.e. compound Spitz nevi), although 
occasionally they may be located entirely at the 
epidermal-dermal junction (junctional Spitz nevi) or 
within the dermis (intradermal). They are symmetrical, 
well-circumscribed and wedge-shaped, and are 
composed of clusters (nests) and bundles (fascicles) of 
melanocytes at the dermo-epidermal junction and/or in 
the dermis. Artifactual clefts are common around 
intraepidermal nests, and there is epidermal hyperplasia 
and prominence of the epidermal granular layer. 
Eosinophilic (Kamino) bodies may be seen in the 
superficial dermis. The melanocytes are epithelioid 
and/or spindle-shaped, and contain moderate to large 
amounts of amphophilic or ground-glass cytoplasm. 
They rarely contain cytoplasmic melanin.  
Their nuclei are relatively large, round to oval in shape, 
and show mild pleomorphism with mostly small, 
round, regular nucleoli.  
Maturation (decrease in nuclear size of melanocytes 
with chromatin becoming darker accompanied by 
reduction in the amount of cytoplasm) with depth is 
present in many cases (Requena et al., 2009). 
Occasional mitotic figures may be seen, but are usually 
located in the superficial dermal component; deep 
mitoses and atypical mitotic figures are not seen in 
Spitz nevi (Barnhill, 2006; Crotty, 1997; Lyon, 2010; 
Mooi, 2002; Walsh et al., 1998).  
 
Figure 2. Compound Spitz nevus from right calf of 24 year old male. 2A) Symmetrical, compound lesion associated with epidermal 
hyperplasia. 2B-C) Lesion is composed of fascicles and nests of epithelioid and spindle-shaped melanocytes with moderate amounts of 
amphophilic cytoplasm. Mitotic activity is infrequent.  
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Figure 3. Desmoplastic/sclerosing Spitz nevus from right thigh of 30 year old male. 3A) Polypoid, relatively symmetrical tumor. 3B-
C) Lesion is composed of large epithelioid and oval cells admixed with abundant collagenous stroma.  
 
Pagetoid intraepidermal scatter of single melanocytes 
or nests of melanocytes (a feature often also present in 
melanomas) in the central portion of the lesion is not 
uncommon. 
Combined melanocytic nevi, comprising a Spitz nevus 
component in conjunction with another nevus type 
[usually acquired nevi] are not uncommon (Scolyer et 
al., 2004). Less common are histologic variants such as 
desmoplastic/sclerosing, angiomatoid, myxoid and 
plexiform Spitz nevi (Lyon, 2010), and pigmented 




No recurrence if completely excised. May infrequently 




Atypical Spitz Tumor (AST) 
Epidemiology 
May present at any age, although they are frequently 
diagnosed in the first two decades. 
Clinics 
Clinically, ASTs may show some features in common 
with Spitz nevi, although they exhibit one or more 
worrisome characteristics, such as large size, variable 
pigmentation, asymmetry or ulceration. 
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Figure 4. Pigmented spindle cell nevus from right thigh of 11 year old female, 7mm in diameter. 4A) Junctional tumor composed of 
numerous junctional nests of pigmented melanocytes. Melanophages are present at the base of the lesion. 4B) The melanocytes are 
oval or spindle-shaped, and contain melanin pigment. Pagetoid suprabasilar spread of single melanocytes and nests of melanocytes is 
present in this image from the center of the tumor. 
 
Pathology 
AST is a heterogeneous group of tumors, from which 
several categories are emerging with the advent of 
molecular genetic studies.  
The common features of AST are spitzoid features, in 
which cytologic or architectural atypia exceeds that 
seen in Spitz nevi, but is insufficient for a definitive 
diagnosis of melanoma.  
The atypical features that may lead to a spitzoid tumor 
being labeled "AST" include: architectural asymmetry; 
lack of circumscription; lack of maturation with depth; 
substantial nuclear pleomorphism; increased cellularity; 
confluent or sheet-like growth; deep mitotic figures; 
atypical mitotic figures; and extension into subcutis 
(Barnhill et al., 1999; Walsh et al., 1998).  
Although these criteria are also seen in melanoma, they 
are present to a lesser degree and extent in ASTs.  
It is because of the difficulty in determining the line of 
demarcation between AST and melanoma on the basis 
of histologic criteria that AST is a poorly reproducible 
diagnosis.  
Some authors have suggested categorization of AST 
into tumors at low and high risk for metastasis on the 
basis of a combination of histologic criteria (Spatz et 
al., 1999; Walsh et al., 1998), but these classifications 
are not in widespread use.  
Recent advances in molecular pathology have 
identified several subcategories of ASTs raising the 
prospect of a refined classification and risk assessment 
using molecular markers. 
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Emerging categories of Atypical Spitz Tumor: 
1. Desmoplastic Spitz Tumor with HRAS mutations 
HRAS-mutant ASTs show distinctive histopathologic 
and cytogenetic features. They are larger lesions with a 
predominantly intradermal distribution of melanocytes 
in horizontal rather than vertical orientation, have 
marked desmoplasia, characteristic cytologic features 
with epithelioid melanocytes scattering between 
thickened collagen bundles, giving them an infiltrating 
growth pattern. Proliferation rates in the majority of 
these cases are low. The majority shows a distinctive 
cytogenetic abnormality comprised of a high-level copy 
number increase of the entire short arm of chromosome 
11 (Bastian et al., 2000; van Engen-van Grunsven et 
al., 2010). 
2. Nodular Spitz Tumor with BRAF and BAP1 
mutations 
Recently, it was shown that a significant subset of 
atypical Spitz tumors is characterized by the 
concomitant presence of BRAFV600E mutation and loss 
of BAP1 expression, the latter being the result of 
inactivating BAP1 mutation and/or deletions (Wiesner 
et al., 2012).  
These BRAFV600E/BAP1-negative tumors show 
distinctive features.  
They are non-pigmented, dermal tumors composed of 
epithelioid melanocytes with abundant amphophilic 
cytoplasm, well-defined cytoplasmic borders, and 
vesicular, pleomorphic nuclei with prominent nucleoli.  
The cells are arranged in large cohesive nests or 
nodular aggregates.  
 
Figure 5. Atypical Spitz tumor from face of 7 year old female, 2.1mm in thickness, with positive sentinel lymph node biopsy, but 
no recurrence 11 years after diagnosis. 5A) Compound, cellular lesion composed of 5B) epithelioid and oval cells with abundant 
cytoplasm and mild epidermal thickening and hypergranulosis. 5C) Lesional cells show moderate cytologic atypia, including scattered 
mitostic figures. 
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Figure 6. Atypical Spitz tumor with BRAF and BAP1 mutations. 6A) Dome-shaped, fairly symmetrical, cellular compound lesion. 6B) 
Effacement of rete ridges. Lesion is composed of large epithelioid melanocytes admixed with numerous lymphocytes. 6C) Epithelioid 
cells have abundant amphophilic cytoplasm, well-defined cell borders, and large vesicular nuclei with conspicuous nucleoli. 6D) 
Immunohistochemistry shows loss of expression of BAP1 in the nuclei of the tumor cells. Note retention of positive staining in the nuclei 
of epidermal keratinocytes and dermal lymphocytes. 
 
The overlying epidermis is thinned (rather than 
thickened as in Spitz nevi), and the rete ridges are 
effaced. They are often associated with moderate to 
large numbers of tumor-infiltrating lymphocytes 
(Wiesner et al., 2012). Loss of nuclear BAP1 
expression by immunohistochemistry is a reliable 
feature to recognize these lesions. 
These ASTs have also been observed in a newly 
described syndrome caused by monoallelic BAP1 
germline mutations. Individuals with this condition can 
have increased numbers of the ASTs described above, 
and have an increased risk of cutaneous and uveal 
melanoma (Wiesner et al., 2012). Hereditary BAP1 
mutations have also been described in mesothelioma 
(Testa et al., 2011). The appearance of multiple ASTs 
with the features described above thus raises the 
suspicion of germline mutations in the BAP1 tumor 
suppressor gene and should prompt a careful family 
history and physical examination and genetic 
counseling should be considered. 
Treatment 
Complete excision. Sentinel lymph node biopsy, as 
recommended by some physicians, can lead to over-
treatment in patients with ASTs.  
The SLN positivity rate in these tumors is higher (up to 
45%) than that seen in melanoma (15-20%) (Busam et 
al., 2009; Ludgate et al., 2009; Murali et al., 2008), but 
sentinel lymph node positivity does not indicate an 
increased risk of systemic metastatization as poor 
outcomes are rare in the patients, even with positive 
sentinel lymph nodes. 
Evolution 
No recurrence if completely excised. May recur if 
incompletely excised.  
From currently available evidence, they may involve 
regional lymph nodes (identified if SLN biopsy is 
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performed), but progression to distant metastasis or 
death is rare (if "atypical spitzoid tumor" is carefully 
defined). 
Prognosis 




Spitzoid melanoma may occur in children, but are more 
common in adults. 
Clinics 
Commonly occur on the head and the extremities. 
Typically nodular lesions, often >10mm in size, 
exhibiting change in shape/size/color. Usually 
amelanotic, but may be pigmented or variegated in 
color. Clinically, they may resemble hemangiomas, 
pyogenic granulomas, or basal cell carcinomas (Bott et 
al., 2011; Huynh et al., 2005). 
Pathology 
Spitzoid melanomas often have a junctional component 
that consists of irregularly-shaped and unevenly 
distributed nests, often with single melanocytes at the 
periphery [in contrast to Spitz nevi which are usually 
well circumscribed with terminal nests at their 
periphery]. Single melanocytes are not infrequent and 
suprabasilar pagetoid spread (not confined to the 
central portion of the lesion) is common. Melanocytes 
within the nests often lack the cohesion seen in Spitz 
nevi. The invasive component of spitzoid melanoma 
consists of an asymmetric proliferation of large, 
atypical epithelioid and/or spindle-shaped melanocytes, 
which usually lack pigment. Melanocytic nests, when 
present, are irregular and confluent. Maturation, i.e. a 
diminishment in size and/or aggregates of with descent 
into the dermis, is absent, poor or incomplete. Mitotic 
figures, including atypical forms in some cases, are 
present, and are often frequent (>2/mm2) and identified 
in the deepest part of the tumor. The epidermis may be 
uneven in thickness, with areas of atrophy and 
effacement of the rete ridges (in contrast to the 
hyperplasia seen in Spitz nevi). If the melanoma arose 
in a pre-existing Spitz nevus, remnants of the nevus 
may be identified at the periphery of the melanoma. 
Lymphovascular invasion, perineural invasion and 
satellitosis may be present (Barnhill, 2006; Crotty et 
al., 2002; Kamino, 2009; Mooi and Krausz, 2006; 
Walsh et al., 1998). 
Immunohistochemically, HMB-45 tends to show 
heterogeneous staining in the invasive component of 
spitzoid melanomas, including in the deep portion of 
the tumor; in contrast, HMB-45 is usually negative in 
the deeper dermal component of Spitz nevi (Bergman 
et al., 1995). The Ki-67 index in spitzoid melanomas is 
higher (often >10% in the dermal component) than that 
in Spitz nevi  
(Bergman et al., 2001). However, there is considerable 
overlap in these patterns in Spitz nevi and spitzoid 
melanomas, and individual features/characteristics 
cannot be used in isolation to distinguish these tumors. 
Use of cytogenetic techniques such as fluorescence in 
situ hybridization (Gerami et al., 2009) or comparative 
genomic hybridization (Bastian et al., 1999) might be 
more useful adjuncts for this distinction. 
Treatment 
As for melanoma. Complete local excision and, in 
many centers following staging work-up, sentinel 
lymph node biopsy. 
Evolution 
As with all melanomas, spitzoid melanomas are 
malignant tumors, with the potential for distant 
metastasis and to cause death. Their likely clinical 
behavior can be predicted based on a variety of clinical 
and pathologic prognostic factors. 
Prognosis 
Outcome depends on clinical and pathologic factors 
that are known to be prognostic in melanoma [e.g. 
stage, age, Breslow thickness, ulceration, mitotic rate, 
microsatellites, etc.] (Balch et al., 2009). 
Cytogenetics 
Note 
Spitz nevi typically do not show chromosomal copy 
number alterations. Increased DNA copy number of 
11p (which includes the HRAS gene locus) is seen in 
~12% of ASTs and correspond to a type described 
above (Bastian et al., 2000), but is rarely identified in 
melanomas. Two-thirds of cases with 11p copy number 
increase also show oncogenic mutations in HRAS 
(Bastian et al., 2000). Rare cases show gains in 7q, but 
could represent a separate category (Bastian et al., 
1999). 
ASTs of the second category outlined above show an 
increased frequency of deletions of the BAP1 locus at 
chromosome 3p21, sometimes involving larger portions 
of or the entirety of chromosome 3. 
Since ASTs are a heterogeneous group of neoplasms, 
they may show a range of other copy number 
alterations. However, to date no consistent pattern or 
other subgroups have emerged beyond the copy 
number change described above. The presence of 
multiple aberrations (more than 2) is worrisome and 
may indicate that the lesion represents melanoma. 
While, no rigorous analysis of copy number changes in 
spitzoid melanomas has been performed to date, our 
experience is that the genomic regions most frequently 
involved are those described for other melanoma 
subtypes (Curtin et al., 2005). 
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Figure 7. Spitzoid melanoma from the right forearm of a 19 year old patient. The tumor was 1.6mm in thickness and exhibited a 
mitotic rate of 14 per mm2. Sentinel lymph node biopsy was positive, and the patient developed brain metastasis a few years later. 7A) 
Low power view shows a compound spitzoid melanocytic lesion associated with prominent epidermal hyperplasia. 7B) The superficial 
dermal component consists of sheets of monotonous epithelioid cells with hyperchromatic nuclei, increased nuclear:cytoplasmic ratios, 
and numerous mitotic figures. 7C) The deep dermal component consists of atypical cells and the melanocytes lack maturation with depth. 
Occasional mitotic figures are present. 
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Genes involved and proteins 
Note 
Several genetic alterations in melanomas and other 
types of melanocytic nevi have been discovered in 
recent years. However, Spitz tumors have been less 
well characterized, and until recently, the only genomic 
aberrations described were mutations in HRAS 
(Bastian et al., 2000). HRAS-mutant Spitz tumors show 
distinctive histologic features, as described earlier. 
A recent study has discovered that a significant subset 
of atypical Spitz tumors is characterized by the co-
occurrence of BRAFV600E mutation and loss of BAP1 
expression, the latter often associated with BAP1 
mutation (Wiesner et al., 2012). These tumors also 
show distinct morphological features, as described 
above. 
Therefore, there appear to be distinct genetic subsets of 
Spitz tumors (with morphologic correlates), the 
biological and prognostic significance of which is yet 





HRAS belongs to the Ras oncogene family, whose 
members are related to the transforming genes of 
mammalian sarcoma retroviruses. The products 
encoded by these genes function in signal transduction 
pathways. Mutations in HRAS cause Costello 
syndrome, a disease characterized by increased growth 
at the prenatal stage, growth deficiency at the postnatal 
stage, predisposition to tumor formation, mental 
retardation, skin and musculoskeletal abnormalities, 
distinctive facial appearance and cardiovascular 
abnormalities. Defects in HRAS are implicated in a 
variety of cancers, including bladder cancer, follicular 
thyroid cancer, and oral squamous cell carcinoma. 
Multiple transcript variants, which encode different 
isoforms, have been identified for this gene. HRAS 
mutations have been described in ~15% of Spitz nevi 
(Bastian et al., 2000), but have not been identified in 
Spitzoid melanomas (van Engen-van Grunsven et al., 
2010). 
Protein 






BAP1 is a tumor suppressor gene that was thought to 
function in the BRCA1 growth control pathway.  
The protein encoded by this gene localizes to the 
nucleus and it interacts with the RING finger domain of 
the BRCA1 protein. More recently, BAP1 has been 
shown to play a role in chromatin modification by 
forming part of multi-protein complexes (such as the 
polycomb repressive deubiquitinase complex, PR-
DUB) that regulate transcription by modification of 
histones. Germline mutations in BAP1 predispose to 
the development of several different tumor types, 
including epithelioid melanocytic tumors (Wiesner et 
al., 2011), cutaneous melanoma (Wiesner et al., 2011), 
uveal melanoma (Njauw et al., 2012; Wiesner et al., 
2011), mesothelioma (Testa et al., 2011), lung 
adenocarcinoma (Abdel-Rahman et al., 2011), and 
meningioma (Abdel-Rahman et al., 2011). A subset of 
ASTs (~25%) is characterized by BRAFV600E mutation 
and BAP1 loss (Wiesner et al., 2012). 
Protein 
Deubiquitinating enzyme that plays a key role in 
chromatin by mediating deubiquitination of histone 
H2A and HCFC1. Catalytic component of the PR-DUB 
complex, a complex that specifically mediates 
deubiquitination of histone H2A monoubiquitinated at 
Lys-119 [H2AK119ub1].  
Acts as a regulator of cell growth by mediating 
deubiquitination of HCFC1 N-terminal and C-terminal 
chains. Interferes with the BRCA1 and BARD1 
heterodimer activity by inhibiting their ability to 





BRAF encodes a protein belonging to the raf/mil 
family of serine/threonine protein kinases. Mutations in 
BRAF are associated with cardiofaciocutaneous 
syndrome, a disease characterized by heart defects, 
mental retardation and a distinctive facial appearance.  
Mutations in BRAF have also been associated with 
various cancers, including melanoma, thyroid 
carcinoma, colorectal cancer, non-Hodgkin lymphoma, 
and adenocarcinoma of lung. A subset of ASTs (~25%) 
is characterized by BRAFV600E mutation and BAP1 loss 
(Wiesner et al., 2012). 
Protein 
Involved in the transduction of mitogenic signals from 
the cell membrane to the nucleus.  
Plays a role in regulating the MAP kinase/ERKs 
signaling pathway, which affects cell division, 
differentiation, and secretion. 
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